The intra-erythrocytic proliferation of the human malaria parasite Plasmodium falciparum requires massive synthesis of PE (phosphatidylethanolamine) that together with phosphatidylcholine constitute the bulk of the malaria membrane lipids. PE is mainly synthesized de novo by the CDP:ethanolamine-dependent Kennedy pathway. We previously showed that inhibition of PE biosynthesis led to parasite death. In the present study we characterized Pf ECT [P. falciparum CTP:phosphoethanolamine CT (cytidylyltransferase)], which we identified as the rate-limiting step of the PE metabolic pathway in the parasite. The cellular localization and expression of Pf ECT along the parasite life cycle were studied using polyclonal antibodies. Biochemical analyses showed that the enzyme activity follows Michaelis-Menten kinetics. Pf ECT is composed of two CT domains separated by a linker region. Activity assays on recombinant enzymes upon site-directed mutagenesis revealed that the N-terminal CT domain was the only catalytically active domain of Pf ECT. Concordantly, three-dimensional homology modelling of Pf ECT showed critical amino acid differences between the substratebinding sites of the two CT domains. Pf ECT was predicted to fold as an intramolecular dimer suggesting that the inactive C-terminal domain is important for dimer stabilization. Given the absence of PE synthesis in red blood cells, Pf ECT represents a potential antimalarial target opening the way for a rational conception of bioactive compounds.
INTRODUCTION
In eukaryotic cells PE (phosphatidylethanolamine) and PC (phosphatidylcholine) constitute the most abundant structural phospholipids. PE is synthesized by the de novo Kennedy pathway, also named CDP-ethanolamine pathway and by phosphatidylserine decarboxylase, which mediates the transformation of phosphatidylserine into PE (Figure 1 ). In the de novo Kennedy pathway, Etn (ethanolamine) is phosphorylated by an EK (Etn kinase) followed by a ECT [CTP:P-Etn (phosphoEtn CT (cytidylyltransferase); EC 2.7.7.14], which transfers a cytidyl group from CTP to the newly formed P-Etn leading to CDP-Etn. The final step involves a transmembrane ethanolaminephosphotransferase, producing PE [1, 2] (Figure 1 ). Within the Kennedy pathway, ECT is considered to be the rate-controlling step [3] . In mammalian cells, the rate of PE biosynthesis has been shown to be related to not only the supply of CDP-Etn, but also to the availability of diacylglycerol suggesting that the metabolic flux is governed by these two metabolites [4] . Genes coding for ECT have been identified in several eukaryotic organisms such as plants [5, 6] , yeast [7] , the protozoan parasite Trypanosoma brucei [8] and mammalian cells [9, 10] . In the rat and human a single gene expresses two isoforms of ECT, Pcyt2α and Pcyt2β, that differ significantly in their kinetic parameters [1, 11] . It has been suggested that ECT activity is regulated by the expression levels of the two distinct isoforms [12] . All known ECTs possess two CT domains of approximately 140 amino acids that probably result from an internal duplication. They are separated by a variable-sized linker region. Both CT domains of ECTs exhibit the characteristic CTP-binding motif HxGH. The second motif R(T/S)xG(V/I)STT, the signature of the CT superfamily, is less conserved in the C-terminal CT domain. Therefore the functionality of the C-terminal domain has often been questioned [1, 13] . The X-ray three-dimensional structure of hECT (human ECT) has been solved by a Structural Genomics consortium and is available in the PDB (PDB code 3ELB).
In Plasmodium falciparum, the deadliest human malaria parasite, the synthesis of PE is of crucial importance since the parasite membranes are almost exclusively comprised of PE and PC with quasi-absence of other structural lipids such as cholesterol. PE is supplied by the parasitic machinery consisting of the de novo Kennedy pathway and, to a lesser extent, in phosphatidylserine decarboxylation [14] , like in mammalian cells [15] (Figure 1 ). The production of membrane lipids is essential for the asexual intraerythrocytic proliferation of the parasite which corresponds to the symptomatic phase of the disease. Because of their critical role in Plasmodium development and proliferation, phospholipid biosynthetic pathways are potential The precursor Etn is taken up from the host or obtained from serine by serine decarboxylase (SD) [14] pharmacological targets. An antimalarial strategy blocking the rate-limiting steps of PC biosynthesis by the CDP-cholinedependent pathway has been successfully developed through the use of choline analogues [16] [17] [18] . The choline analogue T3 (renamed Albitiazolium) [16] is currently in clinical development for the treatment of severe malaria by parenteral route. De novo PE synthesis also appears essential for the parasite. Etn structural analogues have a deleterious impact on Plasmodium growth at the blood stage [19, 20] . The antimalarial activity of Etn analogues has been correlated with a specific inhibition of PE biosynthesis, whereas the synthesis of PC remained unaffected [20, 21] . Genetic manipulations in the rodent malaria parasite Plasmodium berghei revealed that the Ect gene is necessary for parasite survival [22] .
In the present study we identified and characterized the limiting enzymatic step of the CDP-Etn-dependent pathway in P. falciparum. Quantification of parasite metabolites and kinetic studies of enzymes involved within the pathway show that P. falciparum ECT plays a crucial role, as has been observed previously for its mammalian counterpart. Using polyclonal antibodies we show that Pf ECT is mostly localized within the malaria parasite cytoplasm and its expression profile along the parasite life cycle reveals an increase at the later stages. Taking advantage of various recombinant Pf ECT constructs, we demonstrate that, despite the presence of two CT domains, only the N-terminal one is catalytically active. Finally, the homology three-dimensional structural model of Pf ECT brings insight into the molecular basis of the different catalytic behaviours of CT domains.
EXPERIMENTAL Parasite culture and preparation of parasite extracts
The P. falciparum 3D7 strain [MRA102 from MR4 (Malaria Research and Reference Reagent Resource Center)] was cultured in A + or O + human RBCs (red blood cells) obtained from the local blood bank (Etablissement Français du Sang, France) at 5 % haematocrit in RPMI 1640 (Gibco) supplemented with 0.5 % albumax I (Gibco), 10 μg/ml hypoxanthine (Sigma) and 50 μg/ml gentamycin (Gibco). Suspensions were incubated at 37
• C in a culture gas chamber under a gaseous mixture of 5 % O 2 , 5 % CO 2 and 90 % N 2 . Parasites were synchronized with 5 % sorbitol at two consecutive parasite life cycles [23] . For the enzymatic activity assays mature stage parasites were enriched from parasite cultures by the gelatin floatation method using Plasmion ® (Fresenius Kabi) [24] . The parasites were then lysed by adding an equal volume of water containing a cocktail of anti-proteases (Roche) prior to performing the activity assays.
Analysis of PE pathway metabolites
Erythrocyte suspensions, either infected with P. falciparum or not, were washed twice in RPMI 1640. The erythrocytes were incubated at 20 % haematocrit in 500 μl of RPMI 1640 containing 25 mM Hepes buffer (pH 7.4). Etn incorporation was measured with increasing concentrations of [ 14 C]Etn (4.8 Ci/mol) (16-500 μM; American Radiolabeled Chemicals), either at 37
• C or 4
• C for 1 h. Reactions were stopped at 4
• C and the cells were washed twice with ice-cold 0.9 % NaCl solution. The cellular lipids were extracted according to the procedure of Folch et al. [25] modified by Rock [26] . The organic and aqueous phases of Folch extracts were evaporated and dissolved in 100 μl of chloroform/methanol • C for 20, 35 and 10 min respectively and were stopped by heating the mix at 100
• C for 5 min. For each assay, a sample of 20 μl was spotted on to a TLC silica-gel plate pre-activated at 100
• C for 1 h. Radiolabelled products and substrates of Pf ECT and Pf EK were separated using as developing solvent ethanol/0.5 % NaCl/30 % ammonia [50:50:1 (v/v/v)] and ethanol/2 % ammonia [1:1 (v/v)] respectively. Radioactive spots corresponding to CDP-Etn or PEtn were quantified as described above. All enzyme assays were conducted three times in duplicates. Kinetic data were fitted with the Michaelis-Menten equation and kinetic parameters were calculated from the obtained curves (GraphPad Prism4).
Production of polyclonal antisera and Western blotting
Female BALB/c mice (8-week-old; Charles River Laboratories) were immunized by subcutaneous injections of 20-50 μg of purified recombinant Pf ECT (residues 130-262) emulsified in Freund adjuvant. Pf ECT antisera were collected after the third boost, aliquoted and stored at − 20
• C. Distribution of the endogenous Pf ECT enzyme in the soluble and insoluble fractions of parasite lysates was analysed from schizont stage parasites synchronized as mentioned above. Parasite cultures were treated with 0.01 % saponin for 4 min on ice to permeabilize RBCs and were centrifuged at 1800 g for 10 min. The pellet corresponding to the parasites and the IRBC membranes was washed three times with ice-cold RPMI 1640. Total parasite extracts thus correspond to parasites and the surrounding erythrocyte membranes. The insoluble (membranes) and soluble (parasite cytosol) fractions were obtained upon hypotonic lysis in water with an anti-protease cocktail (Roche) and centrifugation at 100 000 g for 30 min at 4
• C. Uninfected RBC extracts were used as controls. For the three stages of the parasite life cycle, parasites were released from highly synchronized cultures. A total of 15 μg of proteins were loaded per stage, separated by SDS/PAGE (12 % gel) and transferred on to nitrocellulose membrane (Protran, Whatman). Pf Ald (P. falciparum aldolase) was used as loading control. Pf ECT antisera were used at 1:300 dilution and anti-Pf Ald monoclonal IgG were used at a final concentration of 1 μg/ml (Santa Cruz, Biotechnology). Secondary antibody was alkaline phosphatase-conjugated anti-(mouse IgG) (1:6000 dilution; Promega). Pf ECT and Pf Ald bands were revealed by using a BCIP (5-bromo-4-chloroindol-3-yl phosphate)/NBT (Nitro Blue Tetrazolium) colour development substrate (Promega).
Immunofluorescence assays for subcellular localization
To immunolocalize Pf ECT in IRBCs, non-synchronized cultures were fixed for 4 h at room temperature (20 • C) in 4 % paraformaldehyde in PBS followed by two washes with PBS. The cells were permeabilized in 0.1 % Triton X-100 in PBS for 10 min, blocked in 2 % FBS (fetal bovine serum) and incubated with Pf ECT antisera (1:400 dilution) in 2 % FBS for 1 h. After three washes, cells were then incubated with the secondary antibody anti-(mouse IgG) Alexa Fluor Red 594 (Invitrogen) (dilution 1:1000) in 2 % FBS for 1 h. Cells were again washed three times and then mounted on to slides using a Vectashield mounting medium containing DAPI (4 ,6-diamidino-2-phenylindole; Vector Laboratories). Parasites were observed with a Zeiss Axioimager epifluorescence microscope equipped with ApoTome (Carl Zeiss). Images were acquired using a 63× oil-immersion objective lens and DIC (differential interference contrast) for transmitted light. Images were processed with Axiovison software (Carl Zeiss) and ImageJ (MacBiophotonics).
Cloning, expression and purification of recombinant Pf ECTs
The Pf ECT cDNA sequence (PF3D7_1347700) was codonoptimized for expression in Escherichia coli (GenScript) and cloned as a NdeI/BamHI fragment in pET-15b expression vector (Novagen) for production of the N-terminal His 6 -tagged protein. Site-directed mutagenesis (QuikChange, Stratagene) was performed to introduce mutations of histidine residues His 146 and His 422 replaced with alanine. E. coli strain BL21(DE3) cells carrying the plasmids with the Pf ECT constructs were grown at 37
• C to mid-log phase in LB (Luria-Bertani) medium and protein expression was induced with 0.5 mM IPTG (isopropyl β-D-thiogalactopyranoside; Invitrogen) for ∼ 24 h at 16
• C. Bacteria were harvested by centrifugation at 6000 g for 15 min at 4
• C and resuspended in a buffer containing 20 mM Tris/HCl (pH 8), 400 mM NaCl, 2 mM 2-mercaptoethanol, 0.5 % Triton X-100, 1 mg/ml lysozyme and a protease inhibitor cocktail (Roche). The cells were lysed by sonication at 50 % power for 5 min on ice (Digital Sonifier, Branson Ultrasonics). After centrifugation, the supernatant containing Pf ECTs was applied on to a HisTrap HP 5-ml column (GE Healthcare). Pf ECTs were eluted with 250 mM imidazole, 20 mM Tris/HCl (pH 8), 400 mM NaCl and 2 mM 2-mercaptoethanol. The protein fractions were concentrated to a minimum of 1 mg/ml with Amicon centrifugal filter and further purified by gel-filtration chromatography using HiLoad Superdex 200-pg column (GE Healthcare). Protein samples were eluted in 20 mM Tris/HCl (pH 8.0), 400 mM NaCl and 2 mM 2-mercaptoethanol and were analysed by SDS/PAGE (12 % gel). The concentration of purified protein samples were determined by the Bradford method using BSA (Pierce) as a standard.
CD analysis
Purified recombinant proteins (wild-type and mutated Pf ECTs) concentrated to 0.3 mg/ml were used for UV-CD analysis in a buffer containing 20 mM sodium phosphate (pH 7.4) and 2 mM 2-mercaptoethanol. CD spectra were recorded from 195 to 260 nm at 20
• C on a Chirascan CD Spectrophotometer (Applied Photophysics) with a 0.5 cm path-length quartz cell. Data were collected at 0.5-nm intervals and an accumulation time of 1 s. All protein spectra were measured three times and corrected by subtraction of respective buffer spectra. The Pf ECT spectra were analysed with CDNN CD Spectra Deconvolution Software (Applied Photophysics).
Homology modelling
ECT sequences of P. falciparum (UniProtKB/Swiss-Prot accession number Q8IDM2), Saccharomyces cerevisiae (UniProtKB/ Swiss-Prot accession number P33412), rat (UniProtKB/SwissProt accession number O88637), bovine (UniProtKB/Swiss-Prot accession number Q5EA75) and human (UniProtKB/Swiss-Prot accession number Q99447) were aligned using MUSCLE [27] . The structural model for Pf ECT N-and C-terminal CT domains was generated on the basis of the structure of the hECT N-terminal and C-terminal CT domains sharing 38 % and 40 % sequence identity respectively. MODELLER 9v8 [28] was used to perform the homology modelling of the Pf ECT intramolecular dimeric complex using the hECT structure (PDB code 3ELB) as template. The linker region (amino acids 152-186) was removed to reflect the structurally characterized hECT intramolecular dimer. The hECT co-crystallized ligand CMP was used as a constraint in MODELLER to keep the binding site in an appropriate conformation. The final model was chosen based on its low value of the MODELLER objective function, Ramachandran plot (MolProbity) [29] , ProQ [30] scores and visual inspection.
RESULTS AND DISCUSSION

Dynamics of the de novo PE biosynthesis pathway in P. falciparum-infected erythrocytes
The disruption of the essential PE pathway through the use of a pharmacological agent produces an antimalarial effect [20, 21] . In order to determine the most critical step of the pathway, we characterized its three enzymatic steps. The parasite obtains Etn from the plasma or from serine through decarboxylation [14] (Figure 1 ). To characterize the dynamics of the pathway, we quantified the incorporation of radiolabelled Etn in the intermediate metabolites P-Etn, CDP-Etn and the end-product PE at the initial linear phase. We incubated IRBCs with increasing Etn concentrations and subsequently measured the metabolite levels. The amounts of P-Etn, CDP-Etn and PE in the IRBCs increased before reaching a plateau at Etn concentrations above 200 μM ( Figure 2 ). The labelling of CDP-Etn was much lower than that of P-Etn and PE ( Figure 2 ) and the maximal Etn incorporation in CDP-Etn was 8-15-fold lower as compared with P-Etn and PE. The statistical analysis of the correlation between P-Etn and the end-product PE revealed a strong positive relationship (r 2 = 0.96, P < 0.0001) indicating that the labelling of PE was related to the labelling of P-Etn. The levels of PE correlated to a lesser extent with CDP-Etn levels (r 2 = 0.82, P = 0.0017). The results suggested that P-Etn, the substrate of Pf ECT, accumulated and CDP-Etn, the product of Pf ECT, was rapidly transformed in the parasite. In other words, Pf ECT was not using the available substrate as quickly as Pf EK was producing it. This indicated that the enzymatic step catalysed by ECT in Plasmodium-infected erythrocytes was the rate-limiting one of the PE biosynthetic pathway.
Characterization of parasite Pf ECT activity and comparison with Pf EK activity
The parasitic ECT enzymatic activity in P. falciparum extracts was measured by following the formation of CDP-Etn from radiolabelled P-Etn. The substrates and the product were separated by TLC. The rate of catalysis showed a characteristic MichaelisMenten saturation curve with a K m value of 373 + − 123 μM for P-Etn and a V max value of 4.3 + − 0.3 pmol/min/10 7 parasites ( Figure 3A) . For comparative purpose, we characterized the endogenous phosphorylation of Etn into P-Etn performed by Pf EK which is the first step of the CDP-Etn-dependent pathway [21, 31] . The affinity of Pf EK for its substrate Etn was 71 + − 4 μM and the specific activity (V max ) was 39.6 + − 0.1 pmol/min/10 7 parasites ( Figure 3B ). The affinity of Pf ECT for P-Etn was thus approximately 5-fold lower than the affinity of Pf EK for Etn and under optimal conditions Pf ECT was ∼ 4-fold less active than Pf EK ( Table 1 ). The comparison of cellular catalytic activities of Pf EK, Pf ECT and P. knowlesi CEPT (choline/ethanolaminephosphotransferase 1) [32] revealed that Pf ECT exhibited the lowest affinity for its substrate and the lowest specific activity of the enzymes of de novo PE pathway under optimal conditions (Table 1) . In other terms, the first and the last enzymatic reactions of the Kennedy pathway were more efficient than the cytidylation of P-Etn catalysed by Pf ECT. This finding is in agreement with a regulatory role of this enzyme within the pathway. However, the availabilities within the parasite of the metabolites involved in the pathway have to be taken into consideration. The concentration of Etn in adult plasma has been described to be from 5 to 20 μM [33, 34] . In addition, in Plasmodium Etn can also be provided through decarboxylation of serine [14, 35] . This latter pathway supplies less than 5 % of the total pool of P-Etn in the parasite [35] and has therefore not been considered for the following calculation. We quantified the Etn metabolites in the same way as described for Figure 2 , though this time using Etn at physiological concentrations (Supplementary Figure  S1 at http://www.biochemj.org/bj/450/bj4500159add.htm). For an Etn concentration of 10 μM, the observed P-Etn and CDPEtn levels incorporated from Etn in the parasite were found to be ∼ 55 nmol/10 10 IRBCs and ∼ 5 nmol/10 10 IRBCs respectively (Supplementary Figure S1) . Under these conditions and based on the volume of 50 fl for a mature parasite [36] , the concentrations of P-Etn and CDP-Etn within the parasite were calculated to be ∼ 100 μM and ∼ 10 μM respectively. The P-Etn concentration was thus in the range of the K m value of Pf ECT (373 μM). For CTP, the second substrate of the enzyme, the parasite concentration is likely to be lower than the K m value (465 + − 70 μM) of Pf ECT (see below). This suggests that the rate of Pf ECT activity in the parasite grown under standard conditions (without excess of Etn) is mainly limited by the availability of CTP, in addition to the intrinsic kinetic parameters of the enzyme. In mammalian cells, the amount of DAG (diacylglycerol) has also been found to be a limiting factor for PE biosynthesis suggesting that the regulation of the metabolic flux is a multi-factor-dependent process [4] . However, amongst the three enzymatic steps of the PE pathway, the preponderant role of Pf ECT in the metabolic flux as evidenced by the Etn incorporation data and kinetic parameters drove us to thoroughly characterize this enzyme.
Sequence analysis of Pf ECT
The P. falciparum genome database PlasmoDB (http://plasmodb. org/plasmo/) [37] predicts the presence of one gene (PF3D7_1347700) encoding a putative Pf ECT. Amino acid sequence alignment with human, S. cerevisiae and Trypanosoma brucei ECT sequences confirmed the presence of two CT domains in Pf ECT separated by a linker region (Figure 4 and Supplementary Figure S2 at http://www.biochemj.org/ bj/450/bj4500159add.htm). The Pf ECT N-terminal and C-terminal CT domains (approximately 135 amino acids) share 34 % sequence identity, whereas the sequences of the N-terminal CT domain of Pf ECT and of human ECT were found to be 38 % identical. Two conserved motifs, the CTP-binding motif HxGH and the cytidylyltransferase signature motif R(S/T)xG(V/I)STT form the active site of the cytidylyltransferase superfamily. In Pf ECT and other aligned sequences, the CTP-binding motif is present in both CT domains whereas the C-terminal CT signature motif lacks some conserved residues of the R(S/T)xG(V/I)STT consensus motif (Figure 4) . The X-ray three-dimensional structure of hECT (PDB code 3ELB) shows that the protein contains one polypeptide chain, but folds as an intramolecular dimer. The N-terminal CT domain of human ECT interacts with the C-terminal one through the conserved dimerization motifs K 84 Figure S2) . The Pf ECT sequence exhibits two peculiarities: (i) a 130-amino acid N-terminal sequence and (ii) a non-conserved extended region of ∼ 140 amino acids linking the two CT cores (Supplementary Figure S2) .
Expression and purification of recombinant Pf ECT
The coding sequence of Pf ECT as annotated in PlasmoDB was confirmed by cDNA sequencing. A codon-optimized sequence was cloned into pET15b for expression as a N-terminal His 6 -tagged recombinant protein. The soluble protein fraction of the IPTG-induced bacterial culture showed a prominent band on the SDS/PAGE at ∼ 90 kDa. This molecular mass was higher than the expected one at 68 kDa (Supplementary Figure  S2) . The peculiar mobility of Pf ECT could result from a very high content of polar residues and/or the presence of a flexible linker containing atypical amino-acid compositions (stretches of aspartic acid and asparagine residues) [38, 39] (Supplementary Figure S2) . A two-step protocol consisting of Ni 2 + -affinity chromatography followed by gel-filtration chromatography was performed to obtain pure protein at a final concentration of 0.3 mg/ml (Supplementary Figure S3 at http://www.biochemj.org/bj/450/bj4500159add.htm). Recombinant purified Pf ECT was used for cellular and further kinetic characterizations. Figure S4) . We thus observed the same aberrant migration of Pf ECT from parasite extract and from recombinant protein (see above). When infected erythrocytes were sub-fractionated using saponin treatment followed by differential centrifugation, the bulk of Pf ECT was recovered in the soluble cytosolic fraction of parasite extracts ( Figure 5A ). To analyse the expression of Pf ECT along the parasite life cycle immunodetections were performed on highly synchronized cultures. The enzyme appeared to be mainly expressed at the late stages (trophozoite and schizont) ( Figure 5B ). Similar expression profiles were found for Pf EK, Pf CK (P. falciparum choline kinase) [21] and Pf CCT [P. falciparum CCT (CTP:phosphocholine CT); R. Cerdan, A. Contet and H. Vial, unpublished work] involved in the CDP-Etn and in its counterpart CDP-choline pathways. The increase of several enzymes of these biosynthetic pathways is probably connected to the need of phospholipids for membrane formation at the late stages of the parasite life cycle in order to produce up to 32 daughter cells which will subsequently invade new erythrocytes. Apart from its essential role in membrane formation, PE is also involved in other biological processes in eukaryotic cells. For example, PE is the donor of the P-Etn group in glycosyl-phosphatidylinositol anchors [8, 40, 41] . During autophagy, PE is conjugated to the ATG8 protein on autophagosomal membranes [42] . Although no direct evidence of such roles for PE in Plasmodium has been found so far, it cannot be excluded that a part of the synthesized PE could have other functions than the formation of membranes.
The subcellular localization of Pf ECT was also determined by immunofluorescence assays. The signal of the Pf ECT antisera was detected at all parasite stages showing a diffuse and dotted pattern ( Figure 5C ). These data suggested that Pf ECT is present in the cytoplasm. Pf ECT localization was in agreement with the localizations of rat [43] and T. brucei ECT [8] . The immunofluorescence analyses also revealed some regions of higher concentration for Pf ECT. We hypothesize that Pf ECT could be localized near the endoplasmic reticulum membrane in close proximity to the following enzyme within the Kennedy pathway, the transmembrane protein CEPT.
Kinetic characterization of recombinant Pf ECT
Purified recombinant Pf ECT protein incubated with radiolabelled P-Etn and CTP showed a high CT activity which increased linearly with time for at least 20 min. Pf ECT was active over a broad pH range from 6 to 9 and the activity was optimal at pH 8 (Supplementary Figure  S5 at http://www.biochemj.org/bj/450/bj4500159add.htm). The enzymatic activity followed Michaelis-Menten kinetics with respect to both substrates with an apparent K m of 452 + − 86 μM for P-Etn and of 465 + − 70 μM for CTP. The maximal velocity of the enzyme reaction was found to be 3.0 + − 0.3 μmol/min/mg of Pf ECT corresponding to a turnover rate (k cat ) of 3.4 + − 0.3 s − 1 ( Figure 6 and Table 1 ). When 2 mM of radioactive phosphocholine was added as a substrate instead of 2 mM P-Etn, CDP-choline could not be detected (<0.04 μmol/min/mg) attesting that Pf ECT was specific for P-Etn.
Only one CT domain of Pf ECT is catalytically active
All currently known ECT sequences possess two CT domains, but the R(S/T)xG(V/I)STT signature motif of their N-and C-terminal CT domain differ substantially (Figure 4 ). To our knowledge, although the lack of key residues in the C-terminal signature motif sequence has already been mentioned for hECT [13] , no experimental data related to the enzymatic activity of the individual domains is available. To clarify the contribution of each CT domain to the enzymatic activity, various constructs encompassing either the N-terminal (residues 1-276 or 100-276) or the C-terminal (residues 385-573) domain were cloned in pET vector and expressed in E. coli. All attempts resulted in the production of insoluble protein fragments. We then opted for an alternative approach aiming at mutating the individual CT domains of the full-length recombinant Pf ECT enzyme. Several previous biochemical and structural studies indicated the crucial role of the histidine residues of the CTP-binding motif HxGH for the CT activity [13, 44, 45] . For example, for the Bacillus subtilis GCT (CTP:glycerol-3-phosphate CT), mutations of these histidine residues led to a dramatic loss in activity [46] . Therefore we mutated individually the second histidine residue of each Pf ECT CTP-binding motif HxGH to alanine, generating the mutated proteins H146A-Pf ECT and H422A-Pf ECT. CD analysis of both mutated and wild-type enzymes showed that the spectra were overlapping, reflecting the same composition in secondary structures and indicating that the overall folding of Pf ECT was likely to be maintained after the mutation of the histidine residues (Supplementary Figure  S6 at http://www.biochemj.org/bj/450/bj4500159add.htm). ECT enzymatic activity was evaluated on both mutated and the wild-type enzymes under identical conditions. Noticeably, high activity was detected with H422A-Pf ECT, whereas H146A-Pf ECT didn't show any measurable activity up to 2 mM of PEtn ( Figure 6A ). The H422A-Pf ECT activity was linear before reaching a saturation plateau as the substrate concentration increased (Figures 6B and 6C ). The affinity (K m ) of the H422A-Pf ECT was found to be 565 + − 60μM for P-Etn and 364 + − 72 μM for CTP and the k cat value was 4.1 + − 0.6 s − 1 ( Table 1 ). The kinetic values of this mutated enzyme were thus similar to the ones of wild-type Pf ECT (Table 1) suggesting that Pf ECT relies solely on its N-terminal CT domain for its catalytic activity. Strikingly, all ECTs known to date possess two CT domains like Pf ECT, probably resulting from an early event of duplication during evolution. For all the analysed ECT sequences, the CTP-binding motif is conserved in both the N-and C-terminal domains unlike the CT signature motif (Figure 4 ). In the light of our results, it is probable that the C-terminal domain of other eukaryotic ECTs is also catalytically inactive. Within the CT superfamily, bacterial GCT and eukaryotic CCT contain only one CT domain. The X-ray structure of B. subtilis and Staphylococcus aureus GCT [44, 45, 47] and rat CCT [13] revealed that the enzymes fold as homodimers. Pf ECT, and probably other ECTs bearing an active N-terminal domain and an inactive C-terminal domain, likely exhibit a unique mechanism for their catalytic function.
Three-dimensional structural model of Pf ECT The finding that the C-terminal CT domain was catalytically inactive prompted us to question the role of this domain in Pf ECT function. To this end, we built a homology model of the Pf ECT structure based on the X-ray structure of the hECT (residues 18-356), crystallized in presence of CMP (PBD code 3ELB). The hECT structure lacks the co-ordinates of the linker region between the N-and C-terminal CT domains. The three-dimensional structural model of Pf ECT showed a global folding similar to human ECT. The enzyme folded as an intramolecular dimer, both CT domains being in contact.
The Pf ECT structure model adopted an α/β-fold and each CT domain formed a Rossmann fold commonly found in nucleotidebinding proteins ( Figure 7A ). Our particular interest was to compare the substrate binding sites of the N-and C-terminal CT domains of Pf ECT. In depth examination of the substratebinding site of the Pf ECT model revealed important amino acid variations between the N-and the C-terminal domains. Two examples are described here. The arginine residue (Arg 249 ) of the N-terminal CT signature motif R(T/S)xG(V/I)STT probably mediates -stacking interactions with the cytosine ring, like in the hECT crystal structure. The replacement of this arginine residue by a serine (Ser 528 ) in the C-terminal CT domain might prevent CTP binding and stabilization ( Figure 7B ). Another important residue involved in β-phosphate binding is the histidine residue at position 221. This histidine residue is conserved in the N-terminal domains of all ECTs, but not in C-terminal domains (except for human). Instead in Pf ECT, the corresponding arginine (Arg 498 ) probably differs in its position due to its important length ( Figure 7B ). Critical residues for substrate binding differed between the N-and C-terminal site, whereas the amino acids at the dimerization interface were rather conserved in both domains. All available three-dimensional crystal structures of CTs show either homo-or pseudo-dimeric (for internal duplication of hECT) oligomerization states, highlighting the importance of dimerization for this superfamily. Thus the C-terminal CT domain of Pf ECT might allow the enzyme to dimerize by intramolecular contacts. The effect of disruption of the intramolecular dimerization will be interesting to evaluate for Pf ECT function.
In conclusion, the present study showed the essential role played by Pf ECT within the PE biosynthesis pathway of P. falciparum and revealed that only one of both CT domains of Pf ECT is catalytically active. As a follow-up to the present study, a new chemotherapeutic approach could be developed in order to impede the PE pathway by targeting its essential and rate-controlling enzyme. A compound screening might be a route to discover new biologically active molecules against this deadly disease. 
AUTHOR CONTRIBUTION
